All In Biotech

Drug Trial Radar · NCT07772934

VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors

Phase 1/2a Open-label Clinical Trial Evaluating VBC117, an EGFR and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Feb 27, 2029

Study completion May 28, 2029

Sponsor

Lead sponsor
VelaVigo Bio IncIndustry
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and/or recommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies treated with VBC117.

Conditions

  • Advanced Solid Tumors

Interventions

  • VBC117Drug

    VBC117 is a epidermal growth factor receptor (EGFR)x Cadherin-17 (CDH17) bispecific antibody-drug conjugate (ADC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: From time of Informed Consent to 30 days post last dose of VBC117
  2. Incidence of DLTsTime frame: From time of first dose of VBC117 to end of DLT period (approximately 21 days)
  3. Incidence of SAEsTime frame: From time of Informed Consent to 30 days post last dose of VBC117
  4. Incidence of TEAE leading to dose modification or discontinuationTime frame: From time of Informed Consent to 30 days post last dose of VBC117
  5. objective response rate (ORR)Time frame: From first dose of VBC117 to disease progression or death, up to approximately 2 years

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Macquarie University

    Randwick, New South Wales, Australia

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

  • Cancer Care Wollongong

    Wollongong, New South Wales, Australia

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Zhejiang, Hangzhou, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Liaoning Cancer Hospital & Institute

    Shengyang, Liaoning, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai GoBroad Cancer Hospital

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.